Cyanotech (CYAN) 10-Q 7 Aug 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2024	Aug. 02, 2024
Document Information [Line Items]
Entity Central Index Key	0000768408
Entity Registrant Name	Cyanotech Corp
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	0-14602
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	91-1206026
Entity Address, Address Line One	73-4460 Queen Kaahumanu Hwy. #102
Entity Address, City or Town	Kailua-Kona
Entity Address, State or Province	HI
Entity Address, Postal Zip Code	96740
City Area Code	808
Local Phone Number	326-1353
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,959,984

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2024	Mar. 31, 2024
Current assets:
Cash	$ 720,000	$ 707,000
Accounts receivable, net of allowance for credit losses of $11 as of June 30, 2024 and March 31, 2024	2,137,000	2,102,000
Inventories	6,961,000	7,313,000
Prepaid expenses and other current assets	551,000	469,000
Total current assets	10,369,000	10,591,000
Equipment and leasehold improvements, net	9,783,000	10,109,000
Operating lease right-of-use assets, net	4,156,000	4,284,000
Other assets	124,000	128,000
Total assets	24,432,000	25,112,000
Current liabilities:
Accounts payable	2,311,000	1,439,000
Accrued expenses	587,000	757,000
Customer deposits	278,000	198,000
Operating lease obligations, current portion	536,000	530,000
Short term debt - bank	1,120,000	1,240,000
Line of credit – related party	1,250,000	1,250,000
Current maturities of long-term debt	4,080,000	3,140,000
Total current liabilities	10,162,000	8,554,000
Long-term debt – related party	0	1,000,000
Long-term operating lease obligations	3,610,000	3,744,000
Total liabilities	13,772,000	13,298,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding	0	0
Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 6,948,379 shares at June 30, 2024 and 6,947,246 shares at March 31, 2024	139,000	139,000
Additional paid-in capital	34,624,000	34,576,000
Accumulated deficit	(24,103,000)	(22,901,000)
Total stockholders’ equity	10,660,000	11,814,000
Total liabilities and stockholders’ equity	$ 24,432,000	$ 25,112,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Accounts receivable, allowance for doubtful accounts	$ 11	$ 11
Current maturities of long-term debt	$ 4,080	$ 3,140
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred, authorized shares (in shares)	10,000,000	10,000,000
Preferred, issued shares (in shares)	0	0
Preferred outstanding, shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.02	$ 0.02
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	6,948,379	6,947,246
Common stock, shares outstanding (in shares)	6,948,379	6,947,246
Related Party [Member]
Current maturities of long-term debt	$ 1,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net sales	$ 5,898	$ 5,146
Cost of sales	4,422	3,614
Gross profit	1,476	1,532
Operating expenses:
General and administrative	1,268	1,274
Sales and marketing	1,165	1,276
Research and development	84	191
Total operating expenses	2,517	2,741
Loss from operations	(1,041)	(1,209)
Interest expense, net	(161)	(160)
Loss before income taxes	(1,202)	(1,369)
Income tax expense	0	0
Net loss	$ (1,202)	$ (1,369)
Net loss per share:
Basic (in dollars per share)	$ (0.17)	$ (0.22)
Diluted (in dollars per share)	$ (0.17)	$ (0.22)
Shares used in calculation of net loss per share:
Basic (in shares)	6,948	6,290
Diluted (in shares)	6,948	6,290

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2023	6,271,971
Balance at Mar. 31, 2023	$ 125	$ 33,856	$ (17,634)	$ 16,347
Issuances of vested shares of restricted stock (in shares)	2,278
Issuances of vested shares of restricted stock	$ 0	(1)	0	(1)
Shares withheld for tax payments (in shares)	(835)
Shares withheld for tax payments	$ 0	0	0	0
Share-based compensation expense	0	47	0	47
Net income (loss)	$ 0	0	(1,369)	(1,369)
Issuances of common stock to Directors in lieu of cash (in shares)	17,672
Issuances of common stock to Directors in lieu of cash	$ 1	15	0	16
Net loss	$ 0	0	(1,369)	(1,369)
Balance (in shares) at Jun. 30, 2023	6,291,086
Balance at Jun. 30, 2023	$ 126	33,917	(19,003)	15,040
Balance (in shares) at Mar. 31, 2024	6,947,246
Balance at Mar. 31, 2024	$ 139	34,576	(22,901)	11,814
Issuances of vested shares of restricted stock (in shares)	1,848
Issuances of vested shares of restricted stock	$ 0	0	0	0
Shares withheld for tax payments (in shares)	(715)
Shares withheld for tax payments	$ 0	0	0	0
Share-based compensation expense	0	48	0	48
Net income (loss)	0	0	(1,202)	(1,202)
Net loss	$ 0	0	(1,202)	(1,202)
Balance (in shares) at Jun. 30, 2024	6,948,379
Balance at Jun. 30, 2024	$ 139	$ 34,624	$ (24,103)	$ 10,660

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,202,000)	$ (1,369,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	378,000	407,000
Amortization of debt issue costs and other assets	6,000	10,000
Amortization of operating leases right-of-use assets	128,000	120,000
Share-based compensation expense	48,000	47,000
Provision for credit losses	0	11,000
Net (increase) decrease in assets:
Accounts receivable	(35,000)	(474,000)
Inventories	397,000	201,000
Prepaid expenses and other assets	(81,000)	104,000
Net increase (decrease) in liabilities:
Accounts payable	822,000	744,000
Accrued expenses	(170,000)	(264,000)
Customer deposits	80,000	(12,000)
Operating lease obligations	(128,000)	(118,000)
Other liabilities	0	(3,000)
Net cash provided by (used in) operating activities	243,000	(596,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in equipment and leasehold improvements	(47,000)	(150,000)
Net cash used in investing activities	(47,000)	(150,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on short term debt and line of credit – bank	(120,000)	0
Draws on short term debt and line of credit – bank	0	230,000
Draws on line of credit – related party	0	250,000
Principal payments on long-term debt – bank	(63,000)	(59,000)
Taxes paid related to net share settlement of restricted stock units	0	(1,000)
Net cash (used in) provided by financing activities	(183,000)	420,000
Net increase (decrease) in cash	13,000	(326,000)
Cash at beginning of period	707,000	974,000
Cash at end of period	720,000	648,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	164,000	151,000
Income taxes	$ 0	$ 0

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. ORGANIZATION AND BASIS OF PRESENTATION Cyanotech Corporation (the “Company”), located in Kailua-Kona, Hawaii, was incorporated in the state of Nevada on March 3, 1983, The Company is an agricultural company that produces high value natural products derived from microalgae grown in complex and intricate open-pond agricultural systems on the Kona coast of Hawaii. The Company's products include Hawaiian Spirulina Pacifica BioAstin Hawaiian Astaxanthin The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the instructions to Form 10 X Accordingly, they do not not March 31, 2024 March 31, 2024, 10 June 26, 2024. Liquidity and Going Concern The accompanying condensed consolidated financial statements as of and for the three June 30, 2024 2023, March 31, 2024, not two March 31, 2024 one March 31, 2023. June 2023, not may As of June 30, 2024, March 31, 2024. March 31, 2023, October 13, 2023, August 30, 2024 ( “2023 June 30, 2024 March 31, 2024, 2023 5 The Company also has a loan facility with a related party that allows the Company to borrow up to $2,000,000 on a revolving basis (the “Revolver”). At both June 30, 2024 March 31, 2024, April 12, 2025 ( 5 12 As of June 30, 2024, 2012 August 2032. 2012 2023 March 31, 2024, March 31, 2024, no may In April 2019, April 12, 2021, December 14, 2022, August 14, 2023, 5 12 June 30, 2024 March 31, 2024, April 12, 2025. The Company continues to experience a loss from operations as the impacts from the macroeconomic environment led to lower sales across the Company's portfolio, therefore, the Company continues to rely on its funding sourced to provide liquidity. To address the resulting cash flow challenges, the Company continues to monitor cost savings initiatives implemented in fiscal year 2023, third 2024. Funds generated by operating activities and available cash are the Company’s most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. The Company has developed its operating plan to produce a significant portion of its cash flows necessary to meet all financing requirements, with the remaining need for capital raising. Although the Company has a history of either being in compliance with debt covenants, or obtaining the necessary waivers, execution of its operating plan is dependent on many factors, some of which are not no June 30, 2025.

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES Consolidation The accompanying condensed consolidated financial statements include the accounts of Cyanotech Corporation and its wholly owned subsidiary, Nutrex Hawaii, Inc. (“Nutrex Hawaii” or “Nutrex”, collectively the “Company”). The Company operates in one one Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of any contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the periods reported. Management reviews these estimates and assumptions periodically and reflects the effect of revisions in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions. Cash Cash primarily consists of cash on hand and cash in bank deposits. Concentration Risk A significant portion of revenues and accounts receivables are derived from a few major customers. For the three June 30, 2024, two three June 30, 2023, two Two June 30, 2024 March 31, 2024, Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not not not 90 not Revenue Recognition The Company records revenue based on the five 1 2 3 4 5 may not Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intent to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically 30 one Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the Condensed Consolidated Balance Sheets. During the three June 30, 2024 2023, March 31, 2024 2023, one not Disaggregation of Revenue The following table represents revenue disaggregated by major product line and extraction services for the: ($ in thousands) Three Months June 30, 2024 Three Months June 30, 2023 Packaged sales Astaxanthin packaged $ 3,260 $ 2,809 Spirulina packaged 1,429 1,574 Total packaged sales 4,689 4,383 Bulk sales Astaxanthin bulk 775 299 Spirulina bulk 342 363 Total bulk sales 1,117 662 Contract extraction and R&D services revenue 92 101 Total net sales $ 5,898 $ 5,146 Recent Accounting Pronouncements In November 2023, 2032 07, Segment Reporting (Topic 28 2023 07” 2023 07 December 15, 2023, December 15, 2024, 2023 07 In December 2023, 2023 09, Income Taxes (Topic 740 2023 09” eight 12 2023 09 December 15, 2024, 2023 09 2023 09

Note 3 - Inventories

Note 3 - Inventories	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. INVENTORIES Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first first June 30, 2024 March 31, 2024 (in thousands) Raw materials $ 1,197 $ 1,149 Work in process 1,957 2,195 Finished goods 3,595 3,658 Supplies 212 311 Inventories $ 6,961 $ 7,313 The Company recognizes abnormal production costs, including fixed cost variances from normal production capacity, fixed production overhead costs, idle facilities, freight handling costs and spoilage, as an expense in the period incurred, without adjusting overhead absorption rates. Normal production capacity is defined as the production expected to be achieved over a number of periods or seasons under normal circumstances, taking into account the loss of capacity resulting from planned maintenance. The Company had abnormal production costs capitalization of $22,000 and abnormal production costs of $133,000 to cost of sales for the three June 30, 2024 2023, In fiscal year 2024, 2025, nine not Other non-inventoriable fixed costs of $68,000 and $189,000 were expensed to cost of sales for the three June 30, 2024 2023,

Note 4 - Equipment and Leasehol

Note 4 - Equipment and Leasehold Improvements	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. EQUIPMENT AND LEASEHOLD IMPROVEMENTS Equipment and leasehold improvements consist of the following as of: June 30, 2024 March 31, 2024 (in thousands) Equipment $ 21,947 $ 21,904 Leasehold improvements 15,075 15,075 Furniture and fixtures 419 419 37,441 37,398 Less accumulated depreciation and amortization (27,878 ) (27,500 ) Construction-in-progress 220 211 Equipment and leasehold improvements, net $ 9,783 $ 10,109 Management has determined that no asset impairment existed as of June 30, 2024. three June 30, 2024 2023,

Note 5 - Line of Credit and Lon

Note 5 - Line of Credit and Long-term Debt	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	5. LINE OF CREDIT AND LONG-TERM DEBT Total debt consists of the following as of: June 30, 2024 March 31, 2024 (in thousands) Short-term debt - bank $ 1,120 $ 1,240 Line of credit – related party 1,250 1,250 Long-term debt 3,157 3,220 Long-term debt - related party 1,000 1,000 Unamortized debt issuance costs (77 ) (80 ) Less current maturities (6,450 ) (5,630 ) Total long-term debt – related party $ — $ 1,000 Line of Credit and Term Loans On June 3, 2016, 2012 2023 prime rate no On October 13, 2023, 2023 no August 30, 2024. 2023 no June 30, 2024 March 31, 2024, 2023 2023 In 2012, 2012 August 14, 2012 “2012 2012 2012 The provisions of the 2012 first August 14, 2032, nineteen 19 2012 June 30, 2024 March 31, 2024 first no 2012 June 30, 2024 March 31, 2024, The 2012 one December 31 December 31, 2012. 2012 June 30, 2024 March 31, 2024, Loan Covenants, Violation and Waiver The Company’s 2023 2012 March 31, 2023, not two June 22, 2023, March 31, 2023, March 31, 2024, not third March 31, 2024, no may Although the 2012 August 2032, twelve 2012 Line of Credit and Debt Related Party In April 2019, April 2021. April 2021, April 2024, 12 December 2022, April 2025 August 14, 2023, The balance under the Skywords Note was $1,000,000 at both June 30, 2024 March 31, 2024. June 30, 2024 March 31, 2024, June 30, 2024 March 31, 2024, June 30, 2024 March 31, 2024 first no Future principal payments under the loans at June 30, 2024 Fiscal year payments due (in thousands) Remainder of 2025 $ 4,277 2026 1,000 Total principal payments $ 5,277

Note 6 - Operating Leases

Note 6 - Operating Leases	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. OPERATING LEASES The Company leases facilities, equipment and land under non-cancelable operating leases expiring through 2037. five two two June 30, 2024, 7.3%, three June 30, 2024 2023, Supplemental balance sheet information related to leases consist of the following as of: Operating leases Balance Sheet Classification June 30, 2024 March 31, 2024 (in thousands) Right-of-use assets Operating lease right-of-use assets $ 6,149 $ 6,149 Accumulated lease amortization Operating lease right-of-use assets (1,993 ) (1,865 ) Total right-of-use assets $ 4,156 $ 4,284 Current lease liabilities Operating lease obligations $ 536 $ 530 Non-current lease liabilities Long-term operating lease obligations 3,610 3,744 Total lease liabilities $ 4,146 $ 4,274 Maturities of lease liabilities at June 30, 2024 Payments (in thousands) Remainder of 2025 $ 613 2026 794 2027 801 2028 591 2029 391 Thereafter 2,463 Total undiscounted lease payments 5,653 Less: present value discount (1,507 ) Total lease liability balance $ 4,146

Note 7 - Accrued Expenses

Note 7 - Accrued Expenses	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. ACCRUED EXPENSES Accrued expenses consist of the following as of: June 30, 2024 March 31, 2024 (in thousands) Wages $ 93 $ 234 Vacation 349 327 Interest and legal 48 32 Other accrued expenses 97 164 Total accrued expenses $ 587 $ 757

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES From time to time, the Company may no June 30, 2024.

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	9. SHARE-BASED COMPENSATION The Company has share-based compensation plans, which are more fully described in Note 9, 10 March 31, 2024 June 26, 2024. As of June 30, 2024, two 2016 “2016 2014 “2014 The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans: As of June 30, 2024 Authorized Available Outstanding 2016 Plan 1,300,000 637,973 411,678 2014 Directors Plan 650,000 33,220 12,000 Total 1,950,000 671,193 423,678 Stock Options All stock option grants made under the equity-based compensation plans were issued at exercise prices no 2016 2014 No ten 10 three June 30, 2024 2023, A summary of option activity under the Company’s stock plans for the three June 30, 2024 Option Activity Shares Weighted Price Weighted Average Aggregate Outstanding at March 31, 2024 297,000 $ 2.47 7.1 $ — Outstanding at June 30, 2024 297,000 $ 2.47 6.9 $ — Exercisable at June 30, 2024 205,333 $ 2.83 6.3 $ — The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price optionees would have received if all options had been exercised on the last business day of the period indicated, based on the Company’s closing stock price of $0.33 and $0.29 at June 30, 2024 March 31, 2024, A summary of the Company’s non-vested options for the nine June 30, 2024 Nonvested Options Shares Weighted Nonvested at March 31, 2024 125,000 $ 1.16 Vested (33,333 ) 1.77 Nonvested at June 30, 2024 91,667 $ 0.93 As of June 30, 2024, Restricted Stock Units ( RSUs ) RSUs are service-based awards granted to eligible employees under the 2016 2016 three June 30, 2024 2023, The following table summarizes information related to awarded RSUs: Nonvested Restricted Stock Units Shares Weighted Nonvested restricted stock units at March 31, 2024 130,820 $ 1.23 Vested (1,848 ) 0.94 Forfeited (2,294 ) 0.47 Nonvested restricted stock units at June 30, 2024 126,678 $ 1.24 As of June 30, 2024,

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. INCOME TAXES The Company utilizes its estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss). The Company did not three June 30, 2024 2023, not not The Company is subject to taxation in the United States and eleven may may As of June 30, 2024 2023, In general, the Company's open tax years range from fiscal years ended 2020 2024.

Note 11 - Earnings Per Share

Note 11 - Earnings Per Share	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	11. EARNINGS PER SHARE Basic earnings (loss) per share is computed on the basis of the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed on the basis of the weighted average number of common shares outstanding plus the potentially dilutive effect of outstanding stock options using the treasury stock method. Reconciliations between the numerator and the denominator of the basic and diluted (loss) income per share computations for the three June 30, 2024 2023 Three Months Ended June 30, 2024 Net Loss Shares Per Share (Numerator) (Denominator) Amount (in thousands) Basic and diluted loss per share $ (1,202 ) 6,948 $ (0.17 ) Three Months Ended June 30, 2023 Net Loss Shares Per Share (Numerator) (Denominator) Amount (in thousands) Basic and diluted loss per share $ (1,369 ) 6,290 $ (0.22 ) Basic and diluted per share amounts are the same in periods of a net loss because common share equivalents are anti-dilutive when a net loss is recorded. Diluted earnings per share does not three June 30, 2023,

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. RELATED PARTY TRANSACTIONS In April 2019, prime rate April 12, 2021. On April 12, 2021, may not three April 12, 2021, no may On April 12, 2021, two On December 14, 2022, April 12, 2025 may On August 14, 2023, may $1,000,000 At both June 30, 2024 March 31, 2024, June 30, 2024 March 31, 2024, June 30, 2024 March 31, 2024,

Note 13 - Subsequent Events

Note 13 - Subsequent Events	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	13. SUBSEQUENT EVENTS The Company had no

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	5. Other Information None.
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Consolidation The accompanying condensed consolidated financial statements include the accounts of Cyanotech Corporation and its wholly owned subsidiary, Nutrex Hawaii, Inc. (“Nutrex Hawaii” or “Nutrex”, collectively the “Company”). The Company operates in one one
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of any contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the periods reported. Management reviews these estimates and assumptions periodically and reflects the effect of revisions in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Cash primarily consists of cash on hand and cash in bank deposits.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration Risk A significant portion of revenues and accounts receivables are derived from a few major customers. For the three June 30, 2024, two three June 30, 2023, two Two June 30, 2024 March 31, 2024,
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not not not 90 not
Revenue [Policy Text Block]	Revenue Recognition The Company records revenue based on the five 1 2 3 4 5 may not Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intent to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically 30 one Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the Condensed Consolidated Balance Sheets. During the three June 30, 2024 2023, March 31, 2024 2023, one not Disaggregation of Revenue The following table represents revenue disaggregated by major product line and extraction services for the: ($ in thousands) Three Months June 30, 2024 Three Months June 30, 2023 Packaged sales Astaxanthin packaged $ 3,260 $ 2,809 Spirulina packaged 1,429 1,574 Total packaged sales 4,689 4,383 Bulk sales Astaxanthin bulk 775 299 Spirulina bulk 342 363 Total bulk sales 1,117 662 Contract extraction and R&D services revenue 92 101 Total net sales $ 5,898 $ 5,146
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In November 2023, 2032 07, Segment Reporting (Topic 28 2023 07” 2023 07 December 15, 2023, December 15, 2024, 2023 07 In December 2023, 2023 09, Income Taxes (Topic 740 2023 09” eight 12 2023 09 December 15, 2024, 2023 09 2023 09

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	($ in thousands) Three Months June 30, 2024 Three Months June 30, 2023 Packaged sales Astaxanthin packaged $ 3,260 $ 2,809 Spirulina packaged 1,429 1,574 Total packaged sales 4,689 4,383 Bulk sales Astaxanthin bulk 775 299 Spirulina bulk 342 363 Total bulk sales 1,117 662 Contract extraction and R&D services revenue 92 101 Total net sales $ 5,898 $ 5,146

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2024 March 31, 2024 (in thousands) Raw materials $ 1,197 $ 1,149 Work in process 1,957 2,195 Finished goods 3,595 3,658 Supplies 212 311 Inventories $ 6,961 $ 7,313

Note 4 - Equipment and Leaseh_2

Note 4 - Equipment and Leasehold Improvements (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2024 March 31, 2024 (in thousands) Equipment $ 21,947 $ 21,904 Leasehold improvements 15,075 15,075 Furniture and fixtures 419 419 37,441 37,398 Less accumulated depreciation and amortization (27,878 ) (27,500 ) Construction-in-progress 220 211 Equipment and leasehold improvements, net $ 9,783 $ 10,109

Note 5 - Line of Credit and L_2

Note 5 - Line of Credit and Long-term Debt (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	June 30, 2024 March 31, 2024 (in thousands) Short-term debt - bank $ 1,120 $ 1,240 Line of credit – related party 1,250 1,250 Long-term debt 3,157 3,220 Long-term debt - related party 1,000 1,000 Unamortized debt issuance costs (77 ) (80 ) Less current maturities (6,450 ) (5,630 ) Total long-term debt – related party $ — $ 1,000
Schedule of Maturities of Long-Term Debt [Table Text Block]	Fiscal year payments due (in thousands) Remainder of 2025 $ 4,277 2026 1,000 Total principal payments $ 5,277

Note 6 - Operating Leases (Tabl

Note 6 - Operating Leases (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Supplement Balance Sheet Information for Operating Lease [Table Text Block]	Operating leases Balance Sheet Classification June 30, 2024 March 31, 2024 (in thousands) Right-of-use assets Operating lease right-of-use assets $ 6,149 $ 6,149 Accumulated lease amortization Operating lease right-of-use assets (1,993 ) (1,865 ) Total right-of-use assets $ 4,156 $ 4,284 Current lease liabilities Operating lease obligations $ 536 $ 530 Non-current lease liabilities Long-term operating lease obligations 3,610 3,744 Total lease liabilities $ 4,146 $ 4,274
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Payments (in thousands) Remainder of 2025 $ 613 2026 794 2027 801 2028 591 2029 391 Thereafter 2,463 Total undiscounted lease payments 5,653 Less: present value discount (1,507 ) Total lease liability balance $ 4,146

Note 7 - Accrued Expenses (Tabl

Note 7 - Accrued Expenses (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2024 March 31, 2024 (in thousands) Wages $ 93 $ 234 Vacation 349 327 Interest and legal 48 32 Other accrued expenses 97 164 Total accrued expenses $ 587 $ 757

Note 9 - Share-based Compensa_2

Note 9 - Share-based Compensation (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Share-based Compensation Shares Authorized Available and Outstanding by Plan [Table Text Block]	As of June 30, 2024 Authorized Available Outstanding 2016 Plan 1,300,000 637,973 411,678 2014 Directors Plan 650,000 33,220 12,000 Total 1,950,000 671,193 423,678
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Option Activity Shares Weighted Price Weighted Average Aggregate Outstanding at March 31, 2024 297,000 $ 2.47 7.1 $ — Outstanding at June 30, 2024 297,000 $ 2.47 6.9 $ — Exercisable at June 30, 2024 205,333 $ 2.83 6.3 $ —
Schedule of Nonvested Share Activity [Table Text Block]	Nonvested Options Shares Weighted Nonvested at March 31, 2024 125,000 $ 1.16 Vested (33,333 ) 1.77 Nonvested at June 30, 2024 91,667 $ 0.93
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Nonvested Restricted Stock Units Shares Weighted Nonvested restricted stock units at March 31, 2024 130,820 $ 1.23 Vested (1,848 ) 0.94 Forfeited (2,294 ) 0.47 Nonvested restricted stock units at June 30, 2024 126,678 $ 1.24

Note 11 - Earnings Per Share (T

Note 11 - Earnings Per Share (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, 2024 Net Loss Shares Per Share (Numerator) (Denominator) Amount (in thousands) Basic and diluted loss per share $ (1,202 ) 6,948 $ (0.17 ) Three Months Ended June 30, 2023 Net Loss Shares Per Share (Numerator) (Denominator) Amount (in thousands) Basic and diluted loss per share $ (1,369 ) 6,290 $ (0.22 )

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Oct. 13, 2023	Sep. 30, 2023	Aug. 14, 2023	Mar. 31, 2023	Dec. 31, 2022	Apr. 30, 2019
Cash and Cash Equivalents, at Carrying Value	$ 720,000	$ 707,000
Working Capital (Deficit)	207,000	2,037,000
Lines of Credit, Related Party, Current	1,250,000	1,250,000
Long-term Debt and Capital Lease Obligations, Current and Noncurrent	3,157,000
Unsecured Subordinated Loan From Skywords [Member]
Debt Instrument, Face Amount	1,000,000	1,000,000							$ 1,500,000
First Foundation Bank [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity							$ 2,000,000
Line of Credit, Current	1,120,000	1,240,000		$ 1,480,000
Related Party 1 [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 2,000,000		$ 2,000,000	$ 2,000,000		$ 1,000,000
Lines of Credit, Related Party, Current	$ 1,250,000	$ 1,250,000

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual)	3 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Contract with Customer, Liability, Revenue Recognized	$ 45,000	$ 16,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	2	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Number 1 [Member]
Concentration Risk, Percentage	31%	32%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Number 2 [Member]
Concentration Risk, Percentage	13%	18%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers	2	2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage	89%	72%

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Revenue By Product (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net sales	$ 5,898	$ 5,146
Packaged Astaxanthin [Member]
Net sales	3,260	2,809
Packaged Spirulina [Member]
Net sales	1,429	1,574
Packaged Products [Member]
Net sales	4,689	4,383
Bulk Astaxanthin [Member]
Net sales	775	299
Bulk Spirulina [Member]
Net sales	342	363
Bulk Products [Member]
Net sales	1,117	662
Contract Extraction and R&D Services [Member]
Net sales	$ 92	$ 101

Note 3 - Inventories (Details T

Note 3 - Inventories (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Inventory Abnormal Production Costs	$ 22,000	$ 133,000
Non Inventoriable Fixed Costs	$ 68,000	$ 189,000

Note 3 - Inventories - Componen

Note 3 - Inventories - Components of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Raw materials	$ 1,197	$ 1,149
Work in process	1,957	2,195
Finished goods	3,595	3,658
Supplies	212	311
Inventories	$ 6,961	$ 7,313

Note 4 - Equipment and Leaseh_3

Note 4 - Equipment and Leasehold Improvements (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Asset Impairment Charges	$ 0
Depreciation, Depletion and Amortization	$ 378,000	$ 407,000

Note 4 - Equipment and Leaseh_4

Note 4 - Equipment and Leasehold Improvements - Components of Equipment and Leasehold Improvements (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Equipment and leasehold improvements, gross	$ 37,441	$ 37,398
Less accumulated depreciation and amortization	(27,878)	(27,500)
Construction-in-progress	220	211
Equipment and leasehold improvements, net	9,783	10,109
Equipment [Member]
Equipment and leasehold improvements, gross	21,947	21,904
Leasehold Improvements [Member]
Equipment and leasehold improvements, gross	15,075	15,075
Furniture and Fixtures [Member]
Equipment and leasehold improvements, gross	$ 419	$ 419

Note 5 - Line of Credit and L_3

Note 5 - Line of Credit and Long-term Debt (Details Textual) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
	Oct. 13, 2023	Apr. 12, 2021	Aug. 14, 2012	Apr. 30, 2021	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2020	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Aug. 14, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 14, 2022	Apr. 30, 2019
Long-term Debt and Capital Lease Obligations, Current and Noncurrent					$ 3,157,000
Debt Issuance Costs, Current, Net					77,000			$ 80,000
Long-term Debt, Current Maturities, Total					6,450,000			5,630,000
Interest Paid, Excluding Capitalized Interest, Operating Activities					164,000	$ 151,000
Lines of Credit, Related Party, Current					$ 1,250,000			1,250,000
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]		Prime Rate [Member]			Prime Rate [Member]
Unsecured Subordinated Loan [Member]
Long-Term Debt, Gross					$ 1,000,000			$ 1,000,000
Term Loan Agreement, Maturing on August 14, 2032 [Member]
Debt Instrument, Basis Spread on Variable Rate			1%
Proceeds from Issuance of Debt			$ 5,500,000
Debt Instrument Interest Payment Period (Month)			12 months
Debt Instrument Amortization Period (Year)			19 years
Debt Instrument Reference Rate					8.50%			8.50%
Long-term Debt and Capital Lease Obligations, Current and Noncurrent					$ 3,157,000			$ 3,220,000
Debt Instrument One Time Origination and Guaranty Fees					$ 214,500
Debt Instrument Annual Renewal Fee Payable Percentage					0.25%
Debt Instrument Guaranteed Portion					80%
Term Loan Agreement, Promissory Note One [Member]
Proceeds from Issuance of Debt			$ 2,250,000
Term Loan Agreement, Promissory Note Two [Member]
Proceeds from Issuance of Debt			$ 3,250,000
Skywords Note [Member]
Debt Instrument, Basis Spread on Variable Rate					1%
Debt Instrument Reference Rate					8.50%			8.50%
Repayments of Long-term Debt, Total		$ 500,000		$ 500,000
Interest Paid, Excluding Capitalized Interest, Operating Activities		$ 1,900		1,900
Skywords Note [Member] | Unsecured Subordinated Loan [Member]
Debt Instrument, Basis Spread on Variable Rate							1%
Debt Instrument, Face Amount															$ 1,500,000
Long-term Debt, Current Maturities, Total				$ 500,000
Long-Term Debt, Gross					$ 1,000,000			$ 1,000,000
Skywords Amended Note [Member]
Debt Instrument, Basis Spread on Variable Rate		1%
Debt Instrument, Floor Interest Rate		5%		5%
Debt Instrument, Face Amount		$ 500,000												$ 1,000,000
Minimum [Member] | Term Loan Agreement, Maturing on August 14, 2032 [Member]
Debt Instrument, Interest Rate During Period			5.50%
Minimum [Member] | Skywords Note [Member]
Debt Instrument, Interest Rate During Period					5%
First Foundation Bank [Member] | Term Loan Converted From Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate	2%				2%
Debt Instrument, Periodic Payment	$ 40,000
Debt Instrument, Floor Interest Rate	7%
Debt Instrument, Interest Rate During Period					8.50%
First Foundation Bank [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage					5.25%
First Foundation Bank [Member] | Revolving Credit Facility [Member]
Debt Instrument, Basis Spread on Variable Rate					2%
Line of Credit, Current	$ 1,480,000				$ 1,120,000			$ 1,240,000
Line of Credit Facility, Maximum Borrowing Capacity												$ 2,000,000
Related Party 1 [Member] | Revolving Credit Facility [Member]
Debt Instrument, Interest Rate, Stated Percentage					8.50%			8.50%
Line of Credit Facility, Maximum Borrowing Capacity									$ 2,000,000	$ 2,000,000	$ 2,000,000		$ 1,000,000
Lines of Credit, Related Party, Current					$ 1,250,000			$ 1,250,000

Note 5 - Line of Credit and L_4

Note 5 - Line of Credit and Long-term Debt - Summary of Line of Credit and Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Short term debt - bank	$ 1,120	$ 1,240
Unamortized debt issuance costs	(77)	(80)
Less current maturities	(6,450)	(5,630)
Total long-term debt – related party	0	1,000
Line of Credit, Related Party [Member]
Long-term debt	1,250	1,250
Long-term Debt, Excluding Related Party Debt [Member]
Long-term debt	3,157	3,220
Unsecured Subordinated Loan [Member]
Long-term debt	$ 1,000	$ 1,000

Note 5 - Line of Credit and L_5

Note 5 - Line of Credit and Long-term Debt - Future Payments (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Remainder of 2025	$ 4,277
2026	1,000
Total principal payments	$ 5,277

Note 6 - Operating Leases (Deta

Note 6 - Operating Leases (Details Textual)	3 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Operating Lease, Weighted Average Remaining Lease Term (Year)	8 years 10 months 24 days
Operating Lease, Weighted Average Discount Rate, Percent	7.30%
Operating Lease, Cost	$ 203,000	$ 203,000
Solar Lease for Buildings [Member]
Leases, Number of Lease Properties	2
Lessee, Operating Lease, Term of Contract (Month)	84 months
Equipment [Member]
Lessee, Operating Lease, Term of Contract (Month)	48 months

Note 6 - Operating Leases - Sup

Note 6 - Operating Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Right-of-use assets	$ 6,149	$ 6,149
Accumulated lease amortization	(1,993)	(1,865)
Total right-of-use assets	4,156	4,284
Current lease liabilities	536	530
Non-current lease liabilities	3,610	3,744
Total lease liabilities	$ 4,146	$ 4,274

Note 6 - Operating Leases - Ope

Note 6 - Operating Leases - Operating Leases Maturities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Remainder of 2025	$ 613
2026	794
2027	801
2028	591
2029	391
Thereafter	2,463
Total undiscounted lease payments	5,653
Less: present value discount	(1,507)
Total lease liability balance	$ 4,146	$ 4,274

Note 7 - Accrued Expenses - Com

Note 7 - Accrued Expenses - Components of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Wages	$ 93	$ 234
Vacation	349	327
Interest and legal	48	32
Other accrued expenses	97	164
Total accrued expenses	$ 587	$ 757

Note 9 - Share-based Compensa_3

Note 9 - Share-based Compensation (Details Textual)	3 Months Ended
	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($) $ / shares
Number of Shareholder Approved Share-based Compensation Plans	2
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 52,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 4 months 24 days
Share-Based Payment Arrangement, Option [Member] | Employees [Member]
Share-Based Payment Arrangement, Expense	$ 29,000	$ 26,000
Share Price (in dollars per share) | $ / shares	$ 0.33	$ 0.29
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Restricted Stock Units (RSUs) [Member] | Employees [Member]
Share-Based Payment Arrangement, Expense	$ 19,000	$ 21,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 105,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	9 months 18 days

Note 9 - Share-based Compensa_4

Note 9 - Share-based Compensation - Shares Authorized, Available for Future Grant and Outstanding Under Each Plan (Details)	Jun. 30, 2024 shares
Authorized (in shares)	1,950,000
Available (in shares)	671,193
Outstanding (in shares)	423,678
The 2016 Plan [Member]
Authorized (in shares)	1,300,000
Available (in shares)	637,973
Outstanding (in shares)	411,678
2014 Directors Plan [Member]
Authorized (in shares)	650,000
Available (in shares)	33,220
Outstanding (in shares)	12,000

Note 9 - Share-based Compensa_5

Note 9 - Share-based Compensation - Summary of Option Activity Under Stock Plans (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024
Outstanding (in shares)	297,000
Outstanding, weighted average exercise price (in dollars per share)	$ 2.47
Outstanding, weighted average remaining contractual term (Year)	6 years 10 months 24 days	7 years 1 month 6 days
Outstanding (in shares)	297,000	297,000
Outstanding, weighted average exercise price (in dollars per share)	$ 2.47	$ 2.47
Outstanding, aggregate intrinsic value	$ 0
Exercisable (in shares)	205,333
Exercisable, weighted average exercise price (in dollars per share)	$ 2.83
Exercisable, weighted average remaining contractual term (Year)	6 years 3 months 18 days

Note 9 - Share-based Compensa_6

Note 9 - Share-based Compensation - Summary of Non-vested Options (Details)	3 Months Ended
	Jun. 30, 2024 $ / shares shares
Nonvested (in shares) | shares	125,000
Nonvested (in dollars per share) | $ / shares	$ 1.16
Vested (in shares) | shares	(33,333)
Vested (in dollars per share) | $ / shares	$ 1.77
Nonvested (in shares) | shares	91,667
Nonvested (in dollars per share) | $ / shares	$ 0.93

Note 9 - Share-based Compensa_7

Note 9 - Share-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Jun. 30, 2024 $ / shares shares
Nonvested restricted stock units (in shares) | shares	130,820
Nonvested restricted stock units, weighted average grant price (in dollars per share) | $ / shares	$ 1.23
Vested (in shares) | shares	(1,848)
Vested, weighted average grant price (in dollars per share) | $ / shares	$ 0.94
Forfeited (in shares) | shares	(2,294)
Forfeited, weighted average grant price (in dollars per share) | $ / shares	$ 0.47
Nonvested restricted stock units (in shares) | shares	126,678
Nonvested restricted stock units, weighted average grant price (in dollars per share) | $ / shares	$ 1.24

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
Income Tax Expense (Benefit)	$ 0	$ 0
Effective Income Tax Rate Reconciliation, Percent	0%	0%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%
Unrecognized Tax Benefits	$ 0		$ 0

Note 11 - Earnings Per Share (D

Note 11 - Earnings Per Share (Details Textual)	3 Months Ended
	Jun. 30, 2023 shares
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	3,000

Note 11 - Earnings Per Share -

Note 11 - Earnings Per Share - Summary of Reconciliations Between the Numerator and the Denominator of the Basic and Diluted Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net loss	$ (1,202)	$ (1,369)
Basic (in shares)	6,948	6,290
Basic (in dollars per share)	$ (0.17)	$ (0.22)

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 12, 2021	Apr. 30, 2021	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2020	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Aug. 14, 2023	Dec. 31, 2022	Dec. 14, 2022	Apr. 30, 2019
Interest Paid, Excluding Capitalized Interest, Operating Activities			$ 164,000	$ 151,000
Long-Term Debt			5,277,000
Lines of Credit, Related Party, Current			$ 1,250,000			$ 1,250,000
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Prime Rate [Member]		Prime Rate [Member]
Revolving Credit Facility [Member] | Related Party 1 [Member]
Line of Credit Facility, Maximum Borrowing Capacity							$ 2,000,000	$ 2,000,000	$ 2,000,000	$ 1,000,000
Lines of Credit, Related Party, Current			$ 1,250,000			$ 1,250,000
Debt Instrument, Interest Rate, Stated Percentage			8.50%			8.50%
Conversion of Skywords Note Into Revolving Loans [Member]
Debt Conversion, Original Debt, Amount	$ 500,000
Skywords Note [Member]
Debt Instrument, Basis Spread on Variable Rate			1%
Repayments of Long-term Debt, Total	500,000	$ 500,000
Interest Paid, Excluding Capitalized Interest, Operating Activities	1,900	$ 1,900
Skywords Note [Member] | Unsecured Subordinated Loan [Member]
Debt Instrument, Face Amount												$ 1,500,000
Debt Instrument, Basis Spread on Variable Rate					1%
Long-Term Debt			$ 1,000,000			$ 1,000,000
Skywords Amended Note [Member]
Debt Instrument, Face Amount	$ 500,000										$ 1,000,000
Debt Instrument, Basis Spread on Variable Rate	1%
Debt Instrument, Term (Year)	3 years
Debt Instrument, Floor Interest Rate	5%	5%